Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

Share Price is delayed by 15 minutes
Get Live Data
524.00    4.00 (0.77%)
Bid:
524.00
Ask:
528.00
Spread: 4.00 (0.763%)
Market Cap: £867.04m
OCI Live PriceLast checked at - London Stock Exchange

Intraday Oakley Share Chart

Total Voting Rights

1 Aug 2025 07:00

RNS Number : 5033T
Oakley Capital Investments Limited
01 August 2025
 

1 August 2025

Oakley Capital Investments Limited

Total Voting Rights

 

In conformity with Disclosure and Transparency Rule 5.6.1, Oakley Capital Investments Limited1 (the "Company") announces the following:

As of 31 July 2025, the Company had 171,421,749 ordinary shares of £0.01 each in issue and admitted to trading on the London Stock Exchange's main market, none of which were held in treasury.

The total number of voting rights in the Company is 171,421,749. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oakley Capital Investments Limited under the FCA's Disclosure and Transparency Rules.

- ends -

 

For further information please contact:

 

Oakley Capital Limited

+44 20 7766 6900

Steven Tredget

 

Greenbrook

+44 20 7952 2000

Rob White / Michael Russell

 

Deutsche Numis (Financial Adviser & Broker)

+44 20 7260 1000

Nathan Brown / Matt Goss

 

Notes:

LEI Number: 213800KW6MZUK12CQ815

About Oakley Capital Investments Limited ("OCI")

OCI is a closed-ended investment fund trading on the main market of the London Stock Exchange as an Official List Company. OCI aims to provide shareholders with consistent long-term capital growth in excess of the FTSE All-Share Index by providing liquid access to private equity returns through investment in the Oakley Funds.

A video introduction to OCI is available at https://oakleycapitalinvestments.com/videos/

The contents of the OCI website are not incorporated into, and do not form part of, this announcement.

The Oakley Funds

Oakley Capital Private Equity II, Oakley Capital Private Equity III, Oakley Capital IV, Oakley Capital V, Oakley Capital VI, Oakley Capital Origin and Oakley Capital Origin II are unlisted lower-mid to mid-market private equity funds that aim to provide investors with significant long-term capital appreciation. The investment strategy of the Funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement. The Oakley family of funds also includes Oakley PROfounders Fund III and Oakley Touring Venture Fund, which are venture capital funds focused on investments in entrepreneur-led, disruptive, technology led companies.

Oakley Capital, the Investment Adviser

Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.

Important information

Oakley Capital Investments has now been admitted to the Official List of the Financial Conduct Authority. Therefore, the Company is now required to satisfy the eligibility criteria for admission to listing on the Official List is required to comply with the Financial Conduct Authority's Listing Rules, including in relation to transactions with related parties, financial reporting, contents of shareholder circulars and other continuing obligations.

This announcement may include "forward-looking statements". These forward-looking statements are statements regarding the Company's objectives, intentions, beliefs or current expectations with respect to, amongst other things, the Company's financial position, business strategy, results of operations, liquidity, prospects and growth. Forward-looking statements are subject to risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Accordingly the Company's actual future financial results, operational performance and achievements may differ materially from those expressed in, or implied by, the statements. Given these uncertainties, prospective investors are cautioned not to place any undue reliance on such forward-looking statements, which speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the Company's expectations with regard to them or any change in events, conditions or circumstances on which any such statements are based unless required to do so by the Financial Services and Markets Act 2000, the Listing Rules or Prospectus Regulation Rules of the Financial Conduct Authority or other applicable laws, regulations or rules.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRWPUPGMUPAPUG
Date   Source Headline
27th Jan 20215:06 pmRNSDirector Dealing
27th Jan 20217:00 amRNSTrading update for the year ended 31 December 2020
26th Jan 20217:00 amRNSInvestment in idealista
7th Jan 20217:00 amRNSSale of the DWS division of the Daisy Group
22nd Dec 20204:11 pmRNSHolding(s) in Company
11th Dec 20202:33 pmRNSDirector Declaration
4th Dec 20203:58 pmRNSHolding(s) in Company
3rd Dec 20204:50 pmEQSHardman & Co Research: Oakley Capital Investments (OCI): NAV: conservative, robust and with growth upside
3rd Dec 20201:52 pmRNSTransaction in Own Shares
25th Nov 20207:00 amRNSHolding(s) in Company
23rd Oct 20207:00 amRNSDirector/PDMR Shareholding
22nd Oct 20207:00 amRNSAcquisition of WindStar Medical
6th Oct 202012:42 pmRNSHolding(s) in Company
6th Oct 20207:00 amRNSTransaction in Own Shares (Amendment)
2nd Oct 20204:33 pmRNSTransaction in Own Shares
2nd Oct 20207:00 amRNSShare Buy-Back Programme
1st Oct 20207:00 amRNSAcquisition of 7NXT
30th Sep 20201:54 pmRNSAppointment of Non-Executive Director
17th Sep 20207:00 amRNSOakley sells Casa.it to EQT
10th Sep 20207:00 amRNSResults for the six months ended 30 June 2020
1st Sep 20207:20 amEQSHardman & Co Research: Oakley Capital Investments (OCI) - initiation of coverage: 'When it rains gold, put out the bucket'
4th Aug 20203:09 pmRNSHolding(s) in Company
29th Jul 20206:15 pmRNSTransaction in Own Shares
29th Jul 20207:00 amRNSTrading update for the six months ended 30 June 20
15th Jul 20209:30 amRNSKepler Trust Intelligence: New Research
6th Jul 20207:00 amRNSCapital Commitment
30th Jun 20207:00 amRNSDirectorate Change
24th Jun 20206:02 pmRNSDirector Dealing
22nd Jun 202012:22 pmRNSHolding(s) in Company
19th Jun 20205:38 pmRNSDirector Dealing
19th Jun 20207:01 amRNSDirector Dealing
19th Jun 20207:00 amRNSDirector Dealing
18th Jun 20205:57 pmRNSHolding(s) in Company
18th Jun 20204:42 pmRNSTransaction in Own Shares
18th Jun 20207:00 amRNSShare Buy-Back
1st Jun 20202:25 pmRNSDirector Declaration
27th May 20205:01 pmRNSHolding(s) in Company
27th May 20207:00 amRNSResult of Annual General Meeting
22nd May 20204:33 pmRNSTime Out equity fundraise and OCI loan repayment
19th May 20207:00 amRNSDirector Declaration
7th May 20207:00 amRNSDirectorate Change and Total Voting Rights
1st May 20207:00 amRNSNotice of Annual General Meeting
8th Apr 20207:00 amRNSOakley completes sale of investment in Inspired
25th Mar 20207:00 amRNSCOVID-19 Update
20th Mar 20207:00 amRNSAnnual Report and Accounts 2019
18th Mar 20204:22 pmRNSTransaction in own Shares
18th Mar 20207:00 amRNSShare Buy-Back
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
12th Mar 20207:33 amRNSResults analysis from Kepler Trust Intelligence

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.